Persistent clinical response to the anti-TNF-α antibody infliximab in patients with ankylosing spondylitis over 3 years

Rheumatology

Volumn 44, Issue 5, 2005, Pages 670-676

  Braun, J ^a,b,k,l   Baraliakos, X ^a   Brandt, J ^a   Listing, J ^c   Zink, A ^c   Alten, R ^d   Burmester, G ^e   Gromnica Ihle, E ^f   Kellner, H ^g   Schneider, M ⁱ   Sorensen H ^h   Zeidler, H ^j   Sieper, J ^b,c  

^a Rheumatology Medical Centre Ruhrgebiet   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c German Rheumatism Research Center   (Germany)

^d Schlosspark Clinic   (Germany)

^e HUMBOLDT UNIVERSITY   (Germany)

^f Hospital Berlin Buch   (Germany)

^g UNIVERSITY OF MUNICH   (Germany)

^h Immanuel Hospital   (Germany)

ⁱ HEINRICH HEINE UNIVERSITY   (Germany)

^j HANNOVER MEDICAL SCHOOL   (Germany)

^k RUHR UNIVERSITY BOCHUM   (Germany)

^l RHEUMAZENTRUM RUHRGEBIET   (Germany)

more..

Author keywords

Ankylosing spondylitis; Infliximab; TNF

Indexed keywords

ANTINUCLEAR ANTIBODY; C REACTIVE PROTEIN; CREATINE KINASE; INFLIXIMAB; LIVER ENZYME; MONOCLONAL ANTIBODY; PLACEBO; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR DECOY RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 2; TUMOR NECROSIS FACTOR-ALPHA INHIBITOR; TUMOR PROTEIN;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BRONCHITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; ERYTHROCYTE SEDIMENTATION RATE; EUROPE; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; GENERAL CONDITION IMPROVEMENT; HEADACHE; HERPES LABIALIS; HUMAN; INJURY; LIVER TOXICITY; LONG TERM CARE; MALE; MYALGIA; OPEN STUDY; PHARYNGITIS; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCORING SYSTEM; UPPER RESPIRATORY TRACT INFECTION; VERTIGO; VOMITING; BLOOD; DOUBLE BLIND PROCEDURE; DRUG EFFECT; HOSPITALIZATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; QUALITY OF LIFE; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR DECOY RECEPTORS;

EID: 21244449214     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keh584     Document Type: Article

References (24)

1. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A et al. Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donors. Arthritis Rheum 1998;41:58-67.
2. Brandt J, Bollow M, Haberle J, Rudwaleit M, Eggens U, Distler A et al. Studying patients with inflammatory back pain and arthritis of the lower limbs clinically and by magnetic resonance imaging: Many, but not all patients with sacroiliitis have spondyloarthropathy. Rheumatology 1999;38:831-6.
3. Gran JT, Husby G, Hordvik, M. Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromso, northern Norway. Ann Rheum Dis 1985;44:359-67.
4. Saraux A, Guedes C, Allain J, Devauchelle V, Valls I, Lamour A et al. Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rhumatologie de l'Ouest. J Rheumatol 1999;26:2622-7.
5. Kobelt G, Andlin-Sobocki P, Brophy S, Jonsson L, Calin A, Braun J. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade®). Rheumatology 2004;43: 1158-66.
6. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 2002;46:223-31.
7. Boonen A, van der Heijde D, Landewe R, Spoorenberg A, Schouten H, Rutten-van Molken M et al. Work status and productivity costs due to ankylosing spondylitis: Comparison of three European countries. Ann Rheum Dis 2002;61:429-37.
8. Zink A, Listing J, Klindworth C, Zeidler H. The national database of the German Collaborative Arthritis Centres: I. Structure, aims, and patients. Ann Rheum Dis 2001;60:199-206.
9. Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E. New treatment options in spondyloarthropathies: Increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr Opin Rheumatol 2001;13:245-9.
10. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W et al. Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 2002;359:1187-93.
11. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: An open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003;48:2224-33.
12. Bruun J, Brandt J, Listing J, Zink A, Alten R, Burmester G et al. Two-year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 2005;64:229-34.
13. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
14. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
15. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A. Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994;21:1694-8.
16. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83.
17. Medical Outcome Trust. How to score the SF-36 Health Survey. Boston: Medical Outcome Trust, 1994.
18. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
19. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short-term improvement after anti-TNF-α therapy in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438-44.
20. Listing J, Schlittgen R. A nonparametric test for random dropouts. Biom J 2003;45:113-27.
21. Baert F, Noman M, Vermeire S, Van Assche GGDH, Carbonez A et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
22. van der Linden SM, Rentsch HU, Gerber N, Cats A, Valkenburg HA. The association between ankylosing spondylitis, acute anterior uveitis and HLA-B27: The results of a Swiss family study. Br J Rheumatol 1988;27(Suppl. 2):39-41.
23. Maini R, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65.
24. Braun J, Sieper J. Biological therapies in the spondyloarthritides - the current state. Rheumatology 2004;43:1072-84.